IP Library Granted Patent US 7,985,770
Granted Patent B2
US 7,985,770 · App. 11/656,513 · Granted Jul 26, 2011

Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,985,770
App. No.
11/656,513
Granted
Jul 26, 2011
Kind
B2
Abstract

Disclosed is a method for stabilizing a pharmaceutically active bi-cyclic compound of formula (i): comprising the step of: admixing the same with a polyol and/or a fatty acid ester other than glyceride and a composition obtained by the method. In addition a soft gelatin capsule formulation of the compound of formula (I) obtained by incorporating the compound in a soft gelatin capsule shell comprising gelatin and a polyol plasticizer.

Claims (49)

1. A pharmaceutical composition comprising a

(i) a bi-cyclic compound represented by the formula (I):

wherein, A is —CH 2 OH, —COCH 2 OH, —COOH or a functional derivative thereof,

X 1 and X 2 are hydrogen, lower alkyl or halogen;

V 1 and V 2 are carbon or oxygen;

W 1 and W 2 are

wherein R 4 and R 5 are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxy (lower) alkyl with the proviso that R 4 and R 5 are not hydroxy or lower alkoxy at the same time;

Z is a carbon, oxygen, sulfur or nitrogen;

R 1 is a saturated or unsaturated bivalent lower-medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halogen, lower alkyl, hydroxy, oxo, aryl or heterocyclic group;

R 2 is a saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkyl, lower alkoxy, lower alkanoyloxy, lower cycloalkyl, lower cycloalkyloxy, aryl, aryloxy, heterocyclic group or heterocyclicoxy group; lower cycloalkyl; lower cycloalkyloxy; aryl, aryloxy, heterocyclic group or heterocyclicoxy group;

R 3 is a hydrogen, a lower alkyl, lower cycloalkyl, aryl or heterocyclic group,

and

(ii) a fatty acid ester which is an ester of a fatty acid and an alcohol selected from the group consisting of propylene glycol, polyethylene glycol and a C1-6 monovalent alcohol.

2. The composition of claim 1 , wherein the bi-cyclic compound is the compound of the formula (I), wherein

A is —COOH or functional derivative thereof;

X 1 and X 2 are halogen;

W 1 is ═O, or where one of R 4 and R 5 is hydrogen, another is hydroxy;

W 2 is where R 4 and R 5 are both hydrogen;

Z is oxygen;

R 1 is a saturated or unsaturated bivalent unsubstituted lower-medium aliphatic hydrocarbon residue,

R 2 is a saturated or unsaturated unsubstituted lower-medium aliphatic hydrocarbon residue;

R 3 is a hydrogen.

3. The composition of claim 1 , wherein said fatty acid ester is propylene glycol fatty acid ester.

4. The composition of claim 1 , wherein the fatty acid ester is an ester of a fatty acid and a C1-6 monovalent alcohol.

5. The composition of claim 4 , wherein said fatty acid ester is isopropyl palmitate.

6. The composition of claim 1 , which is in a dosage form suitable for oral administration.

7. The composition of claim 6 , which is formulated as capsule.

8. A soft gelatin capsule formulation of a bi-cyclic compound of formula (I):

wherein, A is —CH 2 OH, —COCH 2 OH, —COOH or a functional derivative thereof;

X 1 and X 2 are hydrogen, lower alkyl or halogen;

V 1 and V 2 are carbon or oxygen;

W 1 and W 2 are

wherein R 4 and R 5 are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxy (lower) alkyl with the proviso that R 4 and R 5 are not hydroxy or lower alkoxy at the same time;

Z is a carbon, oxygen, sulfur or nitrogen;

R 1 is a saturated or unsaturated bivalent lower-medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halogen, lower alkyl, hydroxy, oxo, aryl or heterocyclic group;

R 2 is a saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkyl, lower alkoxy, lower alkanoyloxy, lower cycloalkyl, lower cycloalkyloxy, aryl, aryloxy, heterocyclic group or heterocyclicoxy group; lower cycloalkyl; lower cycloalkyloxy; aryl, aryloxy, heterocyclic group or heterocyclicoxy group;

R 3 is hydrogen, a lower alkyl, lower cycloalkyl, aryl or heterocyclic group,

which comprises:

a soft gelatin capsule shell comprising gelatin and a polyol as a plasticizer, and

a mixture comprising said bi-cyclic compound and a fatty acid ester which is an ester of a fatty acid and an alcohol selected from the group consisting of propylene glycol, polyethylene glycol and a C1-6 monovalent alcohol, which is filled in the shell.

9. The formulation of claim 8 , wherein

A is —COOH or functional derivative thereof;

X 1 and X 2 are halogen;

W 1 is ═O, or where one of R 4 and R 5 is hydrogen, another is hydroxy;

W 2 is where R 4 and R 5 are both hydrogen;

Z is oxygen;

R 1 is a saturated or unsaturated bivalent unsubstituted lower-medium aliphatic hydrocarbon residue;

R 2 is a saturated or unsaturated unsubstituted lower-medium aliphatic hydrocarbon residue;

R 3 is hydrogen.

Assignments (8)
SECURITY INTEREST Recorded Oct 28, 2025
From: STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 072700/0001 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 071913/0691 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →